Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industry TORONTO and ARLINGTON, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light” or the “Company”) and Kala Bio, Inc. (NASDAQ: KALA) (“Kala Bio”) today announced that Red Light has engaged Kala Bio's with its Researgency.ai agentic artificial intelligence platform under world wide license from Younet to support the clinical development strategy for PEX010, the patented botanical psilocybin drug candidate originated by Filament Health Corp. (“Filament”).

AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industry Toronto, Ontario and Arlington, Massachusetts--(Newsfile Corp. - March 18, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Kala Bio, Inc. (NASDAQ: KALA) ("Kala Bio") today announced that Red Light has engaged Kala Bio's Researgency.ai agentic artificial intelligence platform to support the clinical development strategy for PEX010, the patented botanical psilocybin drug candidate originated by Filament Health Corp. ("Filament"). The engagement will deploy Kala Bio's purpose-built AI research agents to assist in clinical planning, protocol optimization and scenario modeling as Red Light advances PEX010 through its regulated drug development program.

Open-source breakthrough demonstrates AI agents can run 100+ experiments overnight-reinforcing the agentic R&D paradigm Researgency.ai is bringing to life sciences with Kala Bio (KALA) Toronto, Ontario--(Newsfile Corp. - March 11, 2026) - Younet.ai, a Toronto-based AI technology company specializing in enterprise-grade private LLM solutions, today announced that the recent release of AutoResearch by AI pioneer Andrej Karpathy provides strong external validation for the autonomous research-agent approach underpinning Researgency.ai, Younet's agentic research platform being developed in collaboration with Kala Bio, Inc. (NASDAQ: KALA). AutoResearch is an open-source tool that enables AI agents to autonomously conduct 100+ machine-learning experiments overnight on a single GPU, demonstrating a step-change in research velocity via continuous agentic iteration.

Platform Rebrand of Researgency.ai; First Purpose-Built AI Agent for Biotech Expected to Ship Within Two Weeks Platform Rebrand of Researgency.ai; First Purpose-Built AI Agent for Biotech Expected to Ship Within Two Weeks

Younet AI Partners with KALA BIO to Deploy AI Infrastructure for the Biotech Industry Vancouver, British Columbia--(Newsfile Corp. - March 9, 2026) - Stock Trend Capital Inc. (CSE: STCQ) (FSE: P0G) (OTC Pink: STOCF) (the "Company" or "Stock Trend") is pleased to provide shareholders with an update regarding its investment in Younet AI ("Younet"), a privately held Canadian company developing artificial-intelligence platforms and tools enabling users to build customized AI models trained on their own data to automate tasks, enhance productivity, and improve workflows and communications. On March 4, 2026, a strategic partnership between Younet AI and KALA BIO Inc. (NASDAQ: KALA), a clinical-stage biopharmaceutical company, was announced.

ARLINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA” or the “Company”), a clinical-stage biopharmaceutical company, today announced a strategic initiative to build a biotechnology industry dedicated, on-premises artificial intelligence (“AI”) infrastructure platform, designed to be deployed directly within biotech and pharmaceutical client environments, enabling companies across the life sciences sector to unlock additional potential of their proprietary biological data without ever surrendering control of it.

ARLINGTON, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), (“KALA” or the “Company”) today announced the successful completion of its loan settlement with Oxford Finance, LLC (“Oxford”), marking a transformational milestone for the Company. The completion of the settlement resolves critical debt obligations.